Pfizer Seeks Dismissal Of Another Bextra Suit

Law360, New York (September 10, 2007, 12:00 AM EDT) -- Weeks after a federal court threw out nine cases targeting Pfizer Inc., the pharmaceutical giant is trying to poke holes through another amended complaint filed against it in the multidistrict litigation over its controversial anti-inflammatory drugs Bextra and Celebrex.

Pfizer, along with defendants Pharmacia Corp. and G.D. Searle LLC, asked the U.S. District Court for the Northern District of California on Monday to dismiss the amended complaint, in which a plaintiff allegedly suffered multiple heart attacks as a result of taking Bextra.

Pfizer claimed that the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.